A Simplified Mechanistic Algorithm for Treating Resistant Hypertension: Efficacy in a Retrospective Study

Journal of Clinical Hypertension

Volumn 14, Issue 4, 2012, Pages 191-197

  Mann, Samuel J ^a   Parikh, Neal S ^b  

^a WEILL CORNELL MEDICAL CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIURETIC AGENT; DOXAZOSIN; SPIRONOLACTONE;

ADULT; AGED; ALGORITHM; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HYPERTENSION; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADRENERGIC BETA-ANTAGONISTS; ALGORITHMS; ANTIHYPERTENSIVE AGENTS; DIURETICS; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; RENIN-ANGIOTENSIN SYSTEM; RETROSPECTIVE STUDIES; TREATMENT FAILURE;

EID: 84859421452     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/j.1751-7176.2012.00605.x     Document Type: Article

References (30)

1. Epstein M. Resistant hypertension: prevalence and evolving concepts. J Clin Hypertens (Greenwich). 2007;9:2-6.
2. Persell SD. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension. 2011;57:1076-1080.
3. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206-1252.
4. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008;51:1403-1419.
5. Mann SJ. Drug therapy for resistant hypertension: simplifying the approach. J Clin Hypertens. 2011;13:120-130.
6. Richards DA, Prichard BN. Clinical pharmacology of labetalol. Br J Clin Pharmacol. 1979;8:89S-93S.
7. Morgan T. Clinical pharmacokinetics and pharmacodynamics of carvedilol. Clin Pharmacokinet. 1994;26:335-346.
8. Frishman W. Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 1. Pharmacodynamic and pharmacokinetic properties. Amer Heart J. 1979;97:663-670.
9. McNeil JJ, Louis WJ. Clinical pharmacokinetics of labetalol. Clin Pharmacokinet. 1984;9:157-167.
10. Esler MD, Krum H, Sobotka PA, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010;376:1903-1909.
11. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547-1559.
12. Salvetti A, Arzilli F. Chronic dose-response curve of enalapril in essential hypertensives. An Italian multicenter study. Am J Hypertens. 1989;2:352-354.
13. Canter D, Frank GJ, Knapp LE, et al. Quinapril and hydrochlorothiazide combination for control of hypertension: assessment by factorial design. J Hum Hypertens. 1994;8:155-162.
14. Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens. 2003;16:925-930.
15. Calhoun DA, White WB. Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension. J Am Soc Hypertens. 2008;2:462-468.
16. Setaro JF, Black HR. Refractory hypertension. N Engl J Med. 1992;327:543-547.
17. Messerli FH, Makani H, Benjo A, et al. Antihypertensive efficacy of hydrochlorothiazide as evaluated by ambulatory blood pressure monitoring: a meta-analysis of randomized trials. J Am Coll Cardiol. 2011;57:590-600.
18. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-2997.
19. Julius S. The blood pressure seeking properties of the central nervous system. J Hypertens. 1988;6:177-185.
20. Mann SJ. Neurogenic essential hypertension revisited: the case for increased clinical and research attention. Am J Hypertens. 2003;16:881-888.
21. Mann SJ, Gerber LM. Low-dose alpha/beta blockade in the treatment of essential hypertension. Am J Hypertens. 2001;14 (6 Pt 1):553-558.
22. Searle M, Dathan R, Dean S, et al. Doxazosin in combination with atenolol in essential hypertension: a double-blind placebo-controlled multicentre trial. Eur J Clin Pharmacol. 1990;39:299-300.
23. Holtzman JL, Kaihlanen PM, Rider JA, et al. Concomitant administration of terazosin and atenolol for the treatment of essential hypertension. Arch Intern Med. 1988;148:539-543.
24. Sachse C, Brockmöller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet. 1997;60:284-295.
25. Kirchheiner J, Heesch C, Bauer S, et al. Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2004;76:302-312.
26. Lennard MS, Silas JH, Freestone S, et al. Oxidation phenotype - a major determinant of metoprolol metabolism and response. N Engl J Med. 1982;307:1558-1560.
27. Lefebvre J, Poirier L, Poirier P, et al. The influence of CYP2D6 phenotype on the clinical response of nebivolol in patients with essential hypertension. Br J Clin Pharmacol. 2007;63:575-582.
28. Prichard BN, Richards DA. Comparison of labetalol with other anti-hypertensive drugs. Br J Clin Pharmacol. 1982;13:41S-47S.
29. ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA. 2000;283:1967-1975.
30. Mann SJ. Pitfalls in diagnosing chronic kidney disease from eGFR (letter). Arch Intern Med. 2009;169:1168-1169.